Loading...
Loading...
QURE| Name | Value |
|---|---|
| Revenues | 11.1M |
| Cost of Revenue | 10.1M |
| Gross Profit | 1.0M |
| Operating Expense | 48.4M |
| Operating I/L | -47.4M |
| Other Income/Expense | -8.0M |
| Interest Income | 5.8M |
| Pretax | -55.4M |
| Income Tax Expense | 0.9M |
| Net Income/Loss | -56.3M |
uniQure N.V. is a gene therapy company focused on developing treatments for genetic and other debilitating diseases. The company's lead program, Etranacogene dezaparvovec (AMT-061), is in Phase III HOPE-B pivotal trial for hemophilia B treatment. uniQure also has a pipeline of gene therapy candidates, including AMT-130 for Huntington's disease, AMT-060 for hemophilia B, AMT-210 for Parkinson's disease, AMT-260 for temporal lobe epilepsy, AMT-240 for autosomal dominant Alzheimer's disease, and AMT-161 for amyotrophic lateral sclerosis.
